This is consistent with preclinical studies, in which IDH1/2 mutant AML suppresses the activity of cytochrome c oxidase and lowers the mitochondrial threshold to trigger apoptosis upon BCL-2 inhibition (78). Here, BCL2 is linked to acute myeloid leukemia.